PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events...
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Artykuł |
| Język: | English |
| Wydane: |
Frontiers Media S.A.
2022-03-01
|
| Seria: | Frontiers in Pharmacology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fphar.2022.854967/full |